TY - JOUR
T1 - Persistent Corneal Epithelial Defects
T2 - A Review Article
AU - Vaidyanathan, Uma
AU - Hopping, Grant C.
AU - Liu, Harry Y.
AU - Somani, Anisha N.
AU - Ronquillo, Yasmyne C.
AU - Hoopes, Phillip C.
AU - Moshirfar, Majid
N1 - Publisher Copyright:
© 2019, Author(s).
PY - 2019
Y1 - 2019
N2 - Persistent corneal epithelial defects (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision loss. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is important to treat the underlying causative condition, which may include an infection, limbal stem cell deficiency, or diabetes, in order to facilitate wound healing. Standard treatments, such as bandage contact lenses (BCLs) and artificial tears (ATs), aim to provide barrier protection to the epithelial layer. Recently-developed medical treatments can target the re-epithelialization process by facilitating access to growth factors and anti-inflammatory agents, and novel surgical techniques can provide re-innervation to the cornea. PEDs should be treated within 7-10 days to avoid secondary complications. These interventions, along with a step-wise approach to management, can be useful in patients with PEDs that are refractory to standard medical treatment. In this review, we discuss the epidemiology, etiology, diagnosis, current and novel management, and prognosis of persistent epithelial defects.
AB - Persistent corneal epithelial defects (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision loss. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is important to treat the underlying causative condition, which may include an infection, limbal stem cell deficiency, or diabetes, in order to facilitate wound healing. Standard treatments, such as bandage contact lenses (BCLs) and artificial tears (ATs), aim to provide barrier protection to the epithelial layer. Recently-developed medical treatments can target the re-epithelialization process by facilitating access to growth factors and anti-inflammatory agents, and novel surgical techniques can provide re-innervation to the cornea. PEDs should be treated within 7-10 days to avoid secondary complications. These interventions, along with a step-wise approach to management, can be useful in patients with PEDs that are refractory to standard medical treatment. In this review, we discuss the epidemiology, etiology, diagnosis, current and novel management, and prognosis of persistent epithelial defects.
KW - Albumins
KW - Epidermal Growth Factor
KW - Fibronectin
KW - Growth Factor
KW - Insulin-Like Growth Factor I
KW - Ophthalmic Solutions
KW - Thymosin Beta-4
UR - https://www.scopus.com/pages/publications/85091311895
M3 - Review article
AN - SCOPUS:85091311895
SN - 2322-4436
VL - 8
SP - 163
EP - 176
JO - Medical Hypothesis, Discovery, and Innovation in Ophthalmology
JF - Medical Hypothesis, Discovery, and Innovation in Ophthalmology
IS - 3
ER -